<DOC>
	<DOCNO>NCT01899144</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , double-dummy , placebo-controlled , single-dose , 5-treatment , 5-period , 5-way crossover study pediatric patient persistent asthma . The primary purpose study compare efficacy safety Albuterol Spiromax ProAir HFA pediatric asthma patient 2 deliver dose level equivalent 90 mcg 180 mcg albuterol base .</brief_summary>
	<brief_title>Efficacy Safety Comparison Albuterol Spiromax® ProAir® Hydrofluoroalkane ( HFA ) Pediatric Patients</brief_title>
	<detailed_description>The study consist screen visit ( SV ) follow 16 day treatment period comprise 5 visit ( TV1-TV5 ) . The treatment period visit separate washout period last 2-7 day . During treatment period visit , force expiratory volume 1 second ( FEV1 ) determine 30 minute immediately prior commencement study medication administration , 5 , 15 , 30 , 45 , 60 , 120 , 180 , 240 , 300 , 360 minute completion study medication administration .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<criteria>1 . Written inform consent/assent sign dated patient and/or parent/caregiver/legal guardian ( appropriate ) conduct study related procedure 2 . Male premenarchal female 411 year age , inclusive , screen visit 3 . Has document physician diagnosis persistent asthma minimum 6 month duration stable least 4 week prior screen visit . The asthma diagnosis must accordance National Asthma Education Prevention Program Guidelines Expert Panel Report 3 ( EPR3 ) 4 . Has ability selfperform spirometry reproducibly per American Thoracic Society ( ATS ) guideline 5 . Has force expiratory volume 1 second ( FEV1 ) 6090 % predict age , height , gender screen visit base pediatric population standard per protocol . Notes : ( 1 ) Predicted value 59.5059.99 % may round 60 % 90.0190.49 % round 90 % . ( 2 ) Patients screen visit fail meet predict spirometry value study entry may allow single attempt requalify another day , must requalify later 16 day follow first attempt . 6 . Demonstrates reversible bronchoconstriction verify 15 % great increase baseline FEV1 within 30 minute follow inhalation 180 mcg albuterol 200 mcg fluticasone propionate per day equivalent ) , leukotriene modifier ( LTM ) , inhaled cromones , β2agonists alone need . The Inhaled corticosteroid ( ICS ) , LTM , cromone dos must stable least 4 week prior screen visit expect maintain duration study 7 . Is maintain lowdose inhaled corticosteroid ( [ ICS ] , less equal 200 mcg fluticasone propionate per day equivalent ) , leukotriene modifier ( LTM ) , inhaled cromones , β2agonists alone need . The ICS , LTM , cromone dos must stable least 4 week prior screen visit expect maintain duration study 8 . Can selfperform peak expiratory flow rate ( PEF ) measurement handheld peak flow meter 9 . Has ability demonstrate acceptable reproducible inhalation technique Spiromax meter dose inhaler ( MDI ) device Other inclusion criterion apply . 1 . Known hypersensitivity albuterol excipients inhaler formulation ( lactose , ethanol , etc . ) 2 . Participation ( receive study medication ) investigational drug trial within 30 day precede screen visit plan participation another investigational drug trial time trial 3 . History severe milk protein allergy 4 . History respiratory infection disorder ( include , limited bronchitis , pneumonia , acute chronic sinusitis , otitis medium , influenza , etc . ) resolve within 4 week precede screen visit 5 . Any asthma exacerbation require oral corticosteroid within 3 month screen visit . A patient must hospitalization asthma within 6 month prior screen visit . 6 . History lifethreatening asthma define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure 7 . Use prohibit concomitant medication within washout period prescribe per protocol prior screen visit . 8 . Use medication asthma allergic rhinitis prohibit per protocol 9 . The dosage require intranasal corticosteroid and/or cromone stable least 2 week prior screen visit . 10 . Treated oral injectable corticosteroid within 6 week screen visit . 11 . Initiation immunotherapy study period dose escalation study period . Patients treat immunotherapy prior screen visit must use stable ( maintenance ) dose ( 90 day ) consider inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Albuterol Spiromax</keyword>
	<keyword>ProAir HFA</keyword>
	<keyword>albuterol sulfate</keyword>
</DOC>